RPS6KA2 and pancreatic neoplasm: So far existing data indicates that fisetin inhibits survival signaling pathways in different tumors, e.g., RSK/YB-1 in melanoma [16], PI3K/AKT in pancreatic cancer [45] and YB-1 in TNBC cells as shown in the present study.